Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a report published on Thursday morning. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

Oragenics stock opened at $0.32 on Thursday. The business has a 50 day moving average of $0.34 and a 200-day moving average of $0.95. The company has a market capitalization of $3.88 million, a P/E ratio of -0.05 and a beta of 0.49. Oragenics has a 1 year low of $0.25 and a 1 year high of $7.74.

Institutional Trading of Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC bought a new stake in Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics at the end of the most recent reporting period. 18.71% of the stock is owned by institutional investors and hedge funds.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.